Peripartum Cardiomyopathy

Details

Peripartum cardiomyopathy (PPCM) is defined as maternal heart failure with systolic dysfunction (LVEF <45%) developing in the last month of pregnancy or in the first 5 months after delivery, in the absence of known preexisting cardiac dysfunction or other identifiable reversible cause. It is a diagnosis of exclusion. PPCM and dilated cardiomyopathy (DCM) share an overlapping genetic spectrum, with pregnancy acting as an environmental "second hit" in susceptible women; their distinction is diagnostically important but sometimes challenging. sources/peripartum-cmp-nejm-2024 sources/cv-pregnancy-aha-2020

Epidemiology

• Complicates ~1 in 2,000 births worldwide; highest rates in Haiti (~1/300) and parts of Nigeria (~1/100) sources/peripartum-cmp-nejm-2024 (rating: high)
• In the US, Black women are 4× more likely to develop PPCM than White women; 2× more likely to have persistent dysfunction; recovery takes 2× as long sources/peripartum-cmp-nejm-2024 (rating: high)
• One-third to one-half of cases co-occur with hypertensive disorders of pregnancy (including preeclampsia); preeclampsia aOR 3.3 for PPCM sources/peripartum-cmp-nejm-2024 sources/cv-pregnancy-aha-2020
• Other strong risk factors: multiple gestations, advanced maternal age, anemia; mode of delivery is not a recognised risk factor
• Leading cause of maternal death in many US regions; ~60% of cardiogenic shock in pregnancy/postpartum is due to PPCM; mortality up to 20%

Clinical Presentation

• Symptoms and signs of HF: dyspnea, orthopnea, elevated JVP, pulmonary rales, peripheral oedema
• Diagnosis frequently delayed — symptoms overlap with normal pregnancy physiology; high index of suspicion required
• 60–90% of cases occur after delivery, with peak incidence in the first postpartum week
• Presentation can be acute and catastrophic (cardiogenic shock); arrhythmia or thromboembolic event may be the presenting feature
• Black women in the US are more likely to present later in the postpartum period — contributing to worse outcomes

Diagnosis

• Echocardiography: LVEF <45% + absence of other structural heart disease; LV dilatation common but not universal
• BNP is usually elevated (unlike normal pregnancy where BNP is stable) — prompts evaluation but is not diagnostic
• CMR: late gadolinium enhancement consistent with myocarditis is uncommon — argues against myocarditis as a primary mechanism
• Endomyocardial biopsy: rarely needed or performed
• Reversible causes to exclude: myocarditis, hypertension-related, underlying valve disease, toxin-induced (alcohol, chemotherapy), ischaemia, preeclampsia-induced pulmonary oedema without systolic dysfunction, PE, SCAD
• Genetic testing should be offered to most patients, even without family history sources/peripartum-cmp-nejm-2024 (rating: high)
• sources/cv-pregnancy-aha-2020 (rating: high)

Pathogenesis — Vasculohormonal Model

PPCM develops predominantly after delivery — temporally discordant with hemodynamic changes of pregnancy, arguing against a simple "failed hemodynamic stress test" hypothesis. Current model: peripartum hormonal imbalances damage the cardiac vasculature in genetically susceptible women. sources/peripartum-cmp-nejm-2024 (rating: high)

Pituitary-derived:

• Prolactin: Cathepsin D cleaves prolactin to a 16-kDa cardiotoxic fragment → damages cardiac vasculature → ischaemia + paracrine signaling → endothelial cells secrete exosomes containing miR-146a → cardiomyocyte apoptosis. This is the mechanistic basis for bromocriptine therapy
• Oxytocin: Secreted to promote lactation; vasculotoxic effects in Marfan syndrome models; definitive PPCM role not established

Placenta-derived:

• sFlt-1 (soluble fms-like tyrosine kinase 1): Decoy receptor for VEGF, abundantly secreted by placental syncytiotrophoblasts in late gestation → cardiovascular rarefaction → PPCM in mice. Explains the epidemiological association with preeclampsia and multiple gestations (both associated with large increases in placental sFlt-1)
• Activin A: Senescence-associated peptide from late-gestation placenta; correlates with subclinical cardiac dysfunction including 1 year post-delivery in preeclampsia
• Progesterone: Suppresses cardiac carbohydrate oxidation (PDK4 upregulation), promotes cardiac hypertrophy, may have direct negative-inotropic effects — sensitises myocardium to further insults
• Relaxin-2: Vasculoprotective hormone that is paradoxically suppressed in PPCM

Other proposed mechanisms (limited evidence): autoimmunity (anti-troponin I antibodies), microchimerism, inflammation, selenium deficiency (mainly parts of Nigeria)

Genetics

• ~15% of PPCM patients carry heterozygous loss-of-function variants in DCM-associated genes; variant frequencies are nearly identical to those in DCM — suggesting a shared genetic spectrum where pregnancy is an environmental second hit sources/peripartum-cmp-nejm-2024 (rating: high)
• The same DCM-predisposing variants increase susceptibility to chemotherapy-induced and alcohol-induced cardiomyopathy — pointing to a common underlying cardiomyocyte vulnerability
• TTN (titin): ~2/3 of identified genetic variants in PPCM; penetrance <5%; does not predict different prognosis
• FLNC (filamin C) and DSP (desmoplakin): associated with ventricular arrhythmias in DCM; gene-specific arrhythmia risk stratification applies to PPCM carriers
• Rare presentations: Danon's disease (LAMP2) and Duchenne's muscular dystrophy (DMD) can present first as PPCM
• Cascade testing of family members is appropriate when a pathogenic variant is identified

Management

BOARD Framework — Acute PPCM (ESC 2018)

Formalised acute PPCM management: sources/cv-pregnancy-esc-2018 (rating: very high)

• Bromocriptine — dopamine agonist suppressing prolactin; 2.5 mg OD ≥1 week in uncomplicated cases (IIbB); 2.5 mg BID ×2 weeks → 2.5 mg OD ×6 weeks if EF <25% or cardiogenic shock (IIbB); always with anticoagulation
• Oral HF therapies — ACEi/ARB/ARNI/MRA/ivabradine contraindicated in pregnancy and breastfeeding; hydralazine + isosorbide dinitrate as substitutes during pregnancy
• Anticoagulants — standard indications; consider prophylactic anticoagulation if EF very low even without thrombus (IIaC); LMWH preferred
• Relaxing agents — hydralazine/nitrates as vasodilators in context of hypertension/severe LV dysfunction/congestion
• Diuretics — loop diuretics for congestion; avoid in uncongested patients (reduces placental perfusion)

Post-Delivery GDMT

• ACEi/ARBs/aldosterone antagonists: initiate post-delivery; continue per HFrEF GDMT
• Sacubitril-valsartan and SGLT2i: no formal pregnancy/breastfeeding safety data; increasingly used by extrapolation from HFrEF evidence
• Most standard HF medications are compatible with breastfeeding; no safety data for ARNi/SGLT2i
• Adrenergic agonists should be avoided in PPCM — low STAT3 sensitises to β-adrenergic toxicity; levosimendan preferred inotrope if needed sources/cv-pregnancy-esc-2018
• Advanced therapies (IABP, percutaneous VAD, ECMO, LVAD) as appropriate given young age and frequent recovery potential; LVAD/transplant required in up to 10% of cases

Device Therapy

• Wearable cardioverter-defibrillator (WCD): preferred over ICD when a defibrillator is indicated — cardiac function frequently recovers; protects during recovery window; avoids premature permanent ICD implantation (limited data; not tested specifically in pregnant patients) sources/cv-pregnancy-esc-2018
• Permanent ICD: only after 6–12 months of optimal therapy without recovery; follows standard guidelines
• CRT: indicated after 6–12 months if LBBB + QRS >130 ms despite optimal therapy

Bromocriptine Evidence

• ESC guidelines recommend consideration in LVEF <35% (COR 2a); US expert consensus is less uniform
• REBIRTH trial (NCT05180773; n=200; randomised vs placebo): expected to complete 2026; will be definitive
• Published evidence: Sliwa 2010 (n=20; open-label proof-of-concept); Hilfiker-Kleiner 2017 (n=60; two dosing regimens, no placebo control); meta-analysis of available data suggests benefit but all studies have significant methodological limitations sources/peripartum-cmp-nejm-2024 (rating: high)
• Always accompany bromocriptine with anticoagulation (LMWH at minimum prophylactic doses)

Medication Withdrawal

• Cellular/molecular recovery lags echocardiographic recovery; contractile reserve abnormalities can persist despite normalised EF (parallel to TRED-HF experience in DCM)
• Reasonable approach: wait ≥1 year after echocardiographic recovery, withdraw one agent at a time, with close long-term monitoring; no PPCM-specific withdrawal trial data exist

Breastfeeding

• In severe HFrEF (NYHA III/IV), breastfeeding is discouraged; stopping lactation reduces metabolic demand and enables optimal HF treatment (IIbB) sources/cv-pregnancy-esc-2018
• Bromocriptine as lactation inhibitor (and PPCM adjunct) is preferred over cabergoline in PPCM; always with anticoagulation

Prognosis

• IPAC study (n=100): LV recovery occurred almost exclusively in the first 6 months postpartum; major cardiovascular events (transplantation, LVAD, death) occurred almost exclusively in women with EF <30% at presentation — EF at presentation is the critical high-risk threshold sources/cv-pregnancy-aha-2020 (rating: high)

• 50% of patients recover LVEF >50% within 6 months; some never recover; LVAD or transplantation in up to 10%; post-transplant survival inferior to age-matched recipients for other indications

• Adverse outcome predictors: low LVEF at presentation, late presentation (>1 week post-delivery), LGE on CMR, LV dilatation, RV dysfunction
• Co-occurring preeclampsia is paradoxically associated with better LV recovery but higher long-term adverse cardiovascular event rates
• Long-term outcomes (>5 years) are poorly studied; mental health impact is substantial (up to 50% meet criteria for depression or PTSD)

mWHO Classification and Contraception

mWHO Classification

• mWHO IV (40–100% maternal event rate; pregnancy not recommended): prior PPCM with any residual LV dysfunction sources/cv-pregnancy-esc-2018 (rating: very high)
• Even with normalised EF, counselling required due to recurrence risk; subsequent pregnancy should be explicitly discouraged if LVEF does not normalise (IIIC)

Contraception

Contraception must be discussed early and before discharge: sources/cv-pregnancy-aha-2020 (rating: high)

• IUD (copper or hormonal): reasonable in all PPCM (mild or severe dysfunction)
• Progestin-only implant/pill: reasonable in all PPCM
• Combined hormonal contraception (CHC): unreasonable even in PPCM with normal/mild systolic dysfunction — risk outweighs benefit

Subsequent Pregnancy

• Recurrence rate 10–50%; recurrent episodes can be worse (including death)
• Lack of LV recovery before subsequent pregnancy is associated with worse outcomes but is not a strong independent predictor
• Multidisciplinary monitoring during and after subsequent pregnancy is mandatory
• Counselling must weigh uncertain risks against the patient's reproductive wishes

Contradictions / Open Questions

• Bromocriptine clinical benefit: ESC COR 2a is based on small, non-placebo-controlled trials; US expert consensus less uniform; REBIRTH trial (2026) results will be definitive. Benefit must be weighed against stopping breastfeeding in resource-limited settings where cessation increases infant mortality >10-fold sources/peripartum-cmp-nejm-2024 sources/cv-pregnancy-aha-2020
• PPCM vs DCM spectrum: Genetic frequencies nearly identical, yet clinical behaviour differs. Whether pregnancy is purely a trigger or also a disease modifier, and how long pregnancy-specific vulnerability persists, is unresolved sources/peripartum-cmp-nejm-2024
• Racial disparities — mechanism: 4× higher incidence and 2× worse outcomes in US Black women; studies suggest socioeconomic factors (neighbourhood deprivation, provider bias) rather than genetics drive this inequity, but evidence is limited sources/peripartum-cmp-nejm-2024
• Medication withdrawal timing: Extrapolated from TRED-HF (DCM); PPCM-specific withdrawal trial data do not exist sources/peripartum-cmp-nejm-2024
• Anticoagulation threshold: No consensus on EF cutoff at which to initiate prophylactic anticoagulation in PPCM in the absence of intracardiac thrombus sources/cv-pregnancy-aha-2020
• Future pregnancy risk quantification: Recurrence risk estimated at 20–50% depending on EF recovery; precise estimation not established sources/cv-pregnancy-aha-2020
• Long-term prognosis: Very limited data beyond 5 years in this young patient population sources/peripartum-cmp-nejm-2024

Connections

• Related to entities/DCM — shared genetic spectrum (TTN, FLNC, DSP, LAMP2, DMD); PPCM as DCM triggered by pregnancy hormones
• Related to concepts/Hypertensive-Disorders-of-Pregnancy — preeclampsia co-occurs in 1/3–1/2 of PPCM; sFlt-1 as shared mechanistic link
• Related to concepts/Cardio-Obstetrics — PPCM is the cardiomyopathy most directly managed by the cardio-obstetrics team
• Related to entities/Heart-Failure — PPCM management follows HF principles with pregnancy-specific adaptations
• Related to entities/Maternal-Health-Disparities — racial disparities in PPCM incidence and outcomes
• Related to concepts/Adverse-Pregnancy-Outcomes — PPCM as an adverse cardiovascular outcome of pregnancy
• Related to concepts/Preeclampsia — preeclampsia aOR 3.3 for PPCM; sFlt-1 shared mechanism
• Related to entities/TTN — most common genetic predisposition (~2/3 of genetic PPCM cases)
• Related to entities/FLNC — arrhythmia risk in PPCM
• Related to entities/DSP — arrhythmia risk in PPCM

Sources

• sources/peripartum-cmp-nejm-2024
• sources/cv-pregnancy-aha-2020
• sources/cv-pregnancy-esc-2018